How it Works: Cytopoint®
Watch the video to learn how Cytopoint, a monoclonal antibody therapy, controls itch and inflammation in dogs with allergic dermatitis and atopic dermatitis.
Monoclonal antibody therapy mimics the natural response to disease by providing highly selective antibodies that specifically target and neutralize only the molecules that are involved in the disease process.
Cytopoint® is an anti-interleukin 31 monoclonal antibody therapy that is designed with a high specificity profile for canine cytokine interleukin 31, allowing veterinarians to target and neutralize a key mediator responsible for the development of pruritus in atopic disease without negative side effects.
For dogs with allergic dermatitis and atopic dermatitis, Cytopoint offers sustained relief and control of the itch and inflammation associated with atopic dermatitis; with a single in-office injection it provides relief within 24 hours that lasts for 4 to 8 weeks 1,2.
With monthly injections, veterinarians restore the quality of life to atopic dogs long term and build a stronger ongoing relationship with their owners.
Watch the video below to learn more about how Cytopoint controls itch and inflammation in dogs with allergic dermatitis and atopic dermatitis.
INDICATION: Cytopoint has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.
References
1 Data on file, Study No. C863R-US-12-018, 2014, Zoetis Inc.
2 Data on file, Study No. C166R-US-17-180, 2018, Zoetis Inc.